MX2018005376A - Derivados de azetidina para formacion de imágenes de tau. - Google Patents
Derivados de azetidina para formacion de imágenes de tau.Info
- Publication number
- MX2018005376A MX2018005376A MX2018005376A MX2018005376A MX2018005376A MX 2018005376 A MX2018005376 A MX 2018005376A MX 2018005376 A MX2018005376 A MX 2018005376A MX 2018005376 A MX2018005376 A MX 2018005376A MX 2018005376 A MX2018005376 A MX 2018005376A
- Authority
- MX
- Mexico
- Prior art keywords
- azetidine derivatives
- tau imaging
- tau
- compound
- imaging
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title abstract 2
- 150000001539 azetidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0444—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona un nuevo compuesto de la fórmula: métodos de preparación de este compuesto, métodos de uso de este compuesto para imágenes tau y preparaciones de formulaciones de formación de imágenes de tau.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254906P | 2015-11-13 | 2015-11-13 | |
| PCT/US2016/060621 WO2017083198A1 (en) | 2015-11-13 | 2016-11-04 | Azetidine derivatives for tau imaging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018005376A true MX2018005376A (es) | 2018-08-01 |
| MX379649B MX379649B (es) | 2025-03-11 |
Family
ID=57389526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005376A MX379649B (es) | 2015-11-13 | 2016-11-04 | Derivados de azetidina para formacion de imágenes de tau. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10301308B2 (es) |
| EP (1) | EP3374358B1 (es) |
| JP (1) | JP2018531978A (es) |
| KR (1) | KR20180061364A (es) |
| CN (1) | CN108290883B (es) |
| AU (1) | AU2016351609B2 (es) |
| BR (1) | BR112018006969B1 (es) |
| CA (1) | CA3003884C (es) |
| DK (1) | DK3374358T3 (es) |
| EA (1) | EA034018B1 (es) |
| ES (1) | ES2864825T3 (es) |
| IL (1) | IL258313B (es) |
| MX (1) | MX379649B (es) |
| PL (1) | PL3374358T3 (es) |
| PT (1) | PT3374358T (es) |
| SA (1) | SA518391527B1 (es) |
| WO (1) | WO2017083198A1 (es) |
| ZA (1) | ZA201802526B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250064417A1 (en) * | 2022-02-03 | 2025-02-27 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
| CN120693337A (zh) * | 2023-02-02 | 2025-09-23 | 伊莱利利公司 | 用于tau成像的新化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003284492A1 (en) * | 2002-12-16 | 2004-07-09 | Bf Research Institute, Inc. | Quinoline derivative as diagnostic probe for disease with tau protein accumulation |
| PT2247558T (pt) | 2008-02-14 | 2022-03-21 | Lilly Co Eli | Novos agentes de imagiologia para deteção de disfunção neurológica |
| NZ593848A (en) * | 2008-12-31 | 2013-09-27 | Avid Radiopharmaceuticals Inc | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof |
| US8691187B2 (en) * | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2013176698A1 (en) | 2012-05-22 | 2013-11-28 | Eli Lilly And Company | Carboline and carbazole based imaging agents for detecting neurological dysfunction |
-
2016
- 2016-11-04 EP EP16798874.0A patent/EP3374358B1/en active Active
- 2016-11-04 US US15/763,608 patent/US10301308B2/en active Active
- 2016-11-04 JP JP2018522120A patent/JP2018531978A/ja not_active Withdrawn
- 2016-11-04 AU AU2016351609A patent/AU2016351609B2/en active Active
- 2016-11-04 DK DK16798874.0T patent/DK3374358T3/da active
- 2016-11-04 PL PL16798874T patent/PL3374358T3/pl unknown
- 2016-11-04 BR BR112018006969-8A patent/BR112018006969B1/pt not_active IP Right Cessation
- 2016-11-04 WO PCT/US2016/060621 patent/WO2017083198A1/en not_active Ceased
- 2016-11-04 ES ES16798874T patent/ES2864825T3/es active Active
- 2016-11-04 PT PT167988740T patent/PT3374358T/pt unknown
- 2016-11-04 CN CN201680066210.8A patent/CN108290883B/zh active Active
- 2016-11-04 EA EA201890799A patent/EA034018B1/ru not_active IP Right Cessation
- 2016-11-04 CA CA3003884A patent/CA3003884C/en active Active
- 2016-11-04 MX MX2018005376A patent/MX379649B/es unknown
- 2016-11-04 KR KR1020187013117A patent/KR20180061364A/ko not_active Withdrawn
-
2018
- 2018-03-22 IL IL258313A patent/IL258313B/en active IP Right Grant
- 2018-04-17 ZA ZA201802526A patent/ZA201802526B/en unknown
- 2018-05-07 SA SA518391527A patent/SA518391527B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180061364A (ko) | 2018-06-07 |
| MX379649B (es) | 2025-03-11 |
| EA034018B1 (ru) | 2019-12-19 |
| BR112018006969A2 (en) | 2018-10-16 |
| HK1257042A1 (zh) | 2019-10-11 |
| SA518391527B1 (ar) | 2021-02-07 |
| EA201890799A1 (ru) | 2018-10-31 |
| ES2864825T3 (es) | 2021-10-14 |
| CA3003884A1 (en) | 2017-05-18 |
| PT3374358T (pt) | 2021-03-31 |
| IL258313A (en) | 2018-05-31 |
| EP3374358A1 (en) | 2018-09-19 |
| ZA201802526B (en) | 2019-10-30 |
| WO2017083198A1 (en) | 2017-05-18 |
| US20180282322A1 (en) | 2018-10-04 |
| BR112018006969B1 (pt) | 2022-04-26 |
| CA3003884C (en) | 2020-04-21 |
| PL3374358T3 (pl) | 2021-07-12 |
| CN108290883A (zh) | 2018-07-17 |
| AU2016351609A1 (en) | 2018-04-19 |
| IL258313B (en) | 2021-04-29 |
| DK3374358T3 (da) | 2021-03-08 |
| EP3374358B1 (en) | 2021-02-17 |
| CN108290883B (zh) | 2021-02-09 |
| US10301308B2 (en) | 2019-05-28 |
| AU2016351609B2 (en) | 2019-08-08 |
| JP2018531978A (ja) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003311A (es) | Sondas para la proyeccion de imagen de la proteina huntingtina. | |
| CR20160141A (es) | Formulaciones de anticuerpos anti-pdl1 | |
| CR20160419A (es) | Nuevos compuestos biciclicos | |
| BR112019001233A2 (pt) | formulação farmacêutica e uso da mesma | |
| GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| CL2018003087A1 (es) | Síntesis de indazoles. | |
| CL2018003085A1 (es) | Síntesis de indazoles | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| CR20170315A (es) | Inhibridores bace 1 selectivos | |
| EA201790892A1 (ru) | Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина | |
| MX2021005891A (es) | Sondas para la proyeccion de imagen de la proteina huntingtina. | |
| IL267917A (en) | A new stable formulation for fxia antibodies | |
| BR112018003331A2 (pt) | sondas para imagear proteína huntingtina | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| MX386798B (es) | Sondas para la proyección de imagen de la proteína huntingtina. | |
| EA201992360A1 (ru) | Кристаллические формы (s)-афоксоланера | |
| EP3682016A4 (en) | FORMULATIONS FOR THE ADMINISTRATION OF COMPOUNDS | |
| MX2016003725A (es) | Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau. | |
| WO2015111085A3 (en) | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof | |
| IL272033A (en) | Methods for making mixed allergen compositions | |
| CL2016001745A1 (es) | Ácido (s)-3'-metil-abscísico y ésteres del mismo | |
| MX2018005376A (es) | Derivados de azetidina para formacion de imágenes de tau. | |
| DK3706710T3 (da) | Formuleringer med forlænget frigivelse til intraartikulære anvendelser |